A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7050 given orally in patients with advanced solid tumors.
Cancer
DRUG: E7050
Maximum Tolerated Dose: the highest dose at which no more than 1 out of 6 patients experiences Dose Limiting Toxicity (DLT) during Cycle 1., Weekly assessments during the first 4 weeks of treatment.
DLTs and adverse events., Weekly assessments during the first 4 weeks of treatment for DLTs and throughout the study for AEs.|Pharmacokinetics (blood and urine)., Weekly assessments of blood during Cycle 1 and every 2 weeks for subsequent cycles and of urine on Day 1 of Cycles 1 and 2.|Pharmacodynamics (blood)., Weekly assessments during Cycle 1, every 2 weeks on Cycle 2, and on Day 1 of subsequent cycles.|Best overall tumor response, duration of response and duration of stable disease assessed according to modified RECIST (Response Evaluation Criteria in Solid Tumors)., At Screening, between Days 21 and 28 of every even cycle, and at the Final Visit.
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7050 given orally in patients with advanced solid tumors.